Signatera

DEVICE2 trials

Sponsors

Hoffmann-La Roche, Nagoya City University

Conditions

Breast Cancer, MetastaticHER2 + Breast CancerMuscle-invasive Bladder Cancer

Phase 3

A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy

Active, not recruitingNCT04660344

Hoffmann-La RocheMuscle-invasive Bladder Cancer

Start: 2021-05-03End: 2026-10-01Updated: 2026-03-27

Unknown Phase

Personalized Detection of ctDNA for Patients With HER2-Positive Metastatic Breast Cancer Patients Who Achieved Durable Response to Anti-HER2 Treatment

Active, not recruitingNCT06663787

Nagoya City UniversityBreast Cancer, Metastatic, HER2 + Breast Cancer

Start: 2024-04-01End: 2026-12-31Target: 50Updated: 2026-05-13

Related Papers

ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer.

2025-10-208 citations

445 The relationship between immune-related adverse events (irAEs) and ctDNA status: exploratory analysis from IMvigor010

Regular and Young Investigator Award Abstracts2023-10-31

Residual circulating tumor DNA after adjuvant chemotherapy effectively predicts recurrence of stage II‐III gastric cancer

Cancer Communications2023-10-1425 citations

IMvigor011: a study of adjuvant atezolizumab in patients with high-risk MIBC who are ctDNA+ post-surgery

Future Oncology2023-03-0162 citations